论文部分内容阅读
目的研究力达霉素辅基蛋白与结肠癌及正常结肠粘膜组织的结合作用,并进一步研究与VEGF在结肠癌中表达的相关性,探讨抗肿瘤抗生素力达霉素在结肠癌治疗中的意义。方法制备抗力达霉素的鼠单克隆抗体,利用免疫组织化学技术,检测力达霉素辅基蛋白在结肠癌及边缘组织组合芯片上的免疫染色,并在多种病理类型结肠癌组织芯片上,平行检测VEGF的表达及力达霉素辅基蛋白的免疫染色,分析两者的相关性。结果在结肠癌及边缘组织组合芯片上,力达霉素辅基蛋白与结肠癌组织结合的阳性率为66.7%(36/45),明显高于正常结肠组织23.8%(10/32)(P<0.05);在多种病理类型结肠癌组织芯片上,可计数比例为88%(62/70),其中,在力达霉素辅基蛋白免疫染色为阳性的病例中,VEGF表达阳性率为76%(29/38),两者呈正相关(P=0.033,r =0.271)。结论力达霉素辅基蛋白可以与结肠癌组织结合,并与VEGF表达有相关性。在结肠癌的临床个体化治疗中,免疫组织化学技术可为力达霉素与其他靶向药物的联合用药提供一定的参考价值。
Objective To study the binding effect of lidamycin cofactor protein on colon carcinoma and normal colonic mucosa and further study the correlation with VEGF expression in colon carcinoma and to explore the significance of antitumor antibiotic Lidamycin in the treatment of colon carcinoma . Methods The mouse monoclonal antibody against daidomycin was prepared and the immunostaining of lidamycin cofactor on the colon cancer and marginal tissue combinational chip was detected by immunohistochemical technique and was detected on various pathological types of colon cancer tissue microarray , The expression of VEGF was detected in parallel and the immunostaining of levomycin prostacyclin was analyzed. The correlation between them was analyzed. Results The positive rate of binding of lidamycin with colon cancer tissues was 66.7% (36/45) in colon cancer and marginal tissue combo chip, which was significantly higher than that in normal colon tissues (23.8%, P <0.05). On a variety of pathological types of colon cancer tissue chips, the countable ratio was 88% (62/70). Among the cases with positive immunohistochemical staining for lidamycin, the positive rate of VEGF expression was 76% (29/38), the two were positively correlated (P = 0.033, r = 0.271). Conclusion Lidamycin cofactor can bind with colon cancer tissue and has a correlation with VEGF expression. In the clinical individualized treatment of colon cancer, immunohistochemistry can provide a certain reference value for the combination of lidamycin and other targeted drugs.